Philadelphia, Pennsylvania--(Newsfile Corp. - January 8, 2024) - A recently filed securities fraud class action complaint alleges that Aldeyra Therapeutics, Inc. (NASDAQ: ALDX), through certain of its officers and directors, made materially false and misleading statements regarding the Company's business, operations, and prospects. Specifically the Company made false and misleading statements about or failed to disclose: (i) the ADX-2191 new drug application ("NDA") did not include adequate and well-controlled investigations and thus failed to show substantial evidence of ADX-2191's effectiveness; (ii) as a result, the FDA was unlikely to approve the ADX-2191 NDA in its current form; (iii) accordingly, the Company had overstated ADX-2191's clinical and/or commercial prospects; and (iv) as a result, the Company's public statements were materially false and misleading at all relevant times.
Current Aldeyra shareholders who have continuously held Aldeyra shares since prior to January 7, 2021, can seek corporate reforms, the return of funds back to company coffers, and a court approved incentive award at no cost to them whatsoever.
If you would like to learn more about this matter, you are encouraged to visit https://grabarlaw.com/the-latest/aldeyra-sahreholder-investigation/, contact Joshua H. Grabar at jgrabar@grabarlaw.com or Mia R. Heller at mheller@grabarlaw.com, or call 267-507-6085.
Attorney Advertising Disclaimer
Contact:
Joshua H. Grabar, Esq.
Grabar Law Office
One Liberty Place
1650 Market Street, Suite 3600
Philadelphia, PA 19103
Tel: 267-507-6085
Email: jgrabar@grabarlaw.com
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/193491
